Tissue Engineering with a Modular RASSL Toolbox
Tissue Engineering with a Modular RASSL Toolbox
批准号:
7822201
负责人:
Bruce R Conklin
金额:
$2.62万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2010-10-31
关键词:
AdoptedAdultAdverse effectsAffectAffinityArrhythmiaArtificial cardiac pacemakerBiological ModelsBone GrowthBrainCardiacCell Culture TechniquesCommunitiesContractsCyclic AMPEchocardiographyEffectivenessElectrocardiogramEmbryoEngineeringEnsureG Protein-Coupled Receptor SignalingG-Protein-Coupled ReceptorsGoalsGrowth and Development functionHealthHeartHeart RateHormonesHumanIn VitroIndividualKnock-in MouseLentivirus VectorLigandsMeasuresModelingMolecularMonitorMorbidity - disease rateMusMuscle CellsPacemakersPathway interactionsPharmaceutical PreparationsPharmacologic SubstancePhenotypePhosphatidylinositolsPhysiologicalPhysiological ProcessesResearchResearch PersonnelResearch Project GrantsSeriesSignal PathwaySignal TransductionSystemTestingTetanus Helper PeptideTissue EngineeringTissuesWorkbonebrain cellembryo monitoringembryonic stem cellflexibilityfunctional restorationheart pacemaker tissuein vivoinsightinterestmeetingsmortalityneurotransmissionprototypepublic health relevancereceptorrecombinaserelease of sequestered calcium ion into cytoplasmresponsesmall moleculetoolvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
We propose to create a flexible polycistronic system for expressing multiple engineered receptors to facilitate the engineering of tissues, such as cardiac cells, brain, and bone. We developed new class of G-protein- coupled receptors (GPCRs) that are called RASSLs (Receptors Activated Solely by a Synthetic Ligand). RASSLs are engineered to be unresponsive to endogenous hormones, yet still activated by small-molecule drugs with nanomolar affinities and relatively few side effects in vivo, making them ideally suited for tissue- engineering studies. Our prototype RASSL (RO1) activates the Gi signaling pathway, inhibiting cAMP formation. When RO1 is expressed in specific tissues, it can affect diverse physiological processes, such as heart rate, remodeling of heart, neurotransmission, and bone growth. We have helped to establish a growing community of researchers who have engineered new RASSLs to activate all the major GPCR pathways, including Gs, which increases cAMP formation, and Gq, which stimulates calcium mobilization. We now propose to tackle the next major challenge for RASSL users. The lack of robust and controllable in vivo delivery systems for individual or multiple RASSLs has hindered wider use of RASSLs by the scientific community. To meet this need, we will develop a flexible system for expressing multiple RASSLs, using a set of common components that will mimic any GPCR signaling combination with these specific aims. Aim 1. To create an in vivo expression system for optimal spatial and temporal control of RASSL expression. Our ultimate goal is to combine Cre and Tet systems for RASSL expression. We will evaluate each strategy independently in a series of three vectors. We will use the Gi-RASSL in the cardiac pacemaker as a model system with robust in vivo responses. Aim 2. To characterize the physiological responses to each major RASSL-induced GPCR-signaling pathway in mouse cardiac pacemaker tissue and ES cells. Gs-, Gi-, and Gq-RASSLs with high and low levels of basal signaling will be expressed in cardiac pacemaker tissue. To define RASSL-induced phenotypes, we use a cell-culture model of ES cell-derived contracting myocytes, as well as developing pacemaker tissue in mouse embryos and cardiac monitoring in adult mice. Aim 3. To determine the physiological effects of co-stimulating multiple GPCR signaling pathways. We will use the 2A polycistronic system to co-express combinations of RASSLs that activate each of the three major signaling pathways. The four signaling combinations in this series will include Gs-Gi, Gs-Gq, Gi-Gq, and Gs-Gi-Gq. We will also use RASSLs that can be activated by a single ligand, so as to insure co-stimulation.
Public Health Relevance Statement (Provided by Applicant): The fundamental importance of this project to human health is to provide powerful new tools for tissue engineers, who are working to restore function to many tissues, such as the heart, brain and bone. RASSLs also provide basic insights into the actions of GPCRs that are the targets of many widely used pharmaceuticals. Finally we are using the cardiac pacemaker as a model system. We hope to gain fundamental insights into cardiac arrhythmias that are a major cause of morbidity and mortality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
-
批准号:10590420
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2021
-
负责人:Bruce R Conklin
-
依托单位:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
-
批准号:10186371
-
项目类别:
-
资助金额:$212.63万
-
财政年份:2021
-
负责人:Bruce R Conklin
-
依托单位:
Core C: Genome Engineering Core
-
批准号:10245028
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2019
-
负责人:Bruce R Conklin
-
依托单位:
Core C: Genome Engineering Core
-
批准号:10471986
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2019
-
负责人:Bruce R Conklin
-
依托单位:
Core C: Genome Engineering Core
-
批准号:10006187
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2019
-
负责人:Bruce R Conklin
-
依托单位:
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
-
批准号:10455604
-
项目类别:
-
资助金额:$72.08万
-
财政年份:2018
-
负责人:Bruce R Conklin
-
依托单位:
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
-
批准号:10249959
-
项目类别:
-
资助金额:$72.08万
-
财政年份:2018
-
负责人:Bruce R Conklin
-
依托单位:
JAX-Gladstone, SCGE Disease Models Studies Supplement
-
批准号:10620067
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2018
-
负责人:Bruce R Conklin
-
依托单位:
Therapeutic genome editing to treat Best disease
-
批准号:9980913
-
项目类别:
-
资助金额:$42.48万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs
-
批准号:9930312
-
项目类别:
-
资助金额:$4.41万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs
-
批准号:9384644
-
项目类别:
-
资助金额:$47.2万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Therapeutic genome editing to treat Best disease
-
批准号:10200060
-
项目类别:
-
资助金额:$41.21万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy
-
批准号:9195146
-
项目类别:
-
资助金额:$45.65万
-
财政年份:2015
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8138279
-
项目类别:
-
资助金额:$62.79万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8328586
-
项目类别:
-
资助金额:$61.65万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8532967
-
项目类别:
-
资助金额:$57.74万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8676918
-
项目类别:
-
资助金额:$60.54万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)
-
批准号:8153362
-
项目类别:
-
资助金额:$23.86万
-
财政年份:2010
-
负责人:Bruce R Conklin
-
依托单位:
GenMAPP-CS, a dynamic resource pathway analysis
-
批准号:7904722
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2009
-
负责人:Bruce R Conklin
-
依托单位:
Cell Production Core
-
批准号:8590752
-
项目类别:
-
资助金额:$18.18万
-
财政年份:2008
-
负责人:Bruce R Conklin
-
依托单位:
海外基金